Prognostic utility of the IPS3 score for predicting outcomes in advanced Hodgkin ’s lymphoma

The ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen has been the standard treatment for advanced Hodgkin ’s lymphoma (aHL) in adults.(1) In the last decade, attempts have been made to improve outcomes with dose-intense regimens like BEACOPP and incorporation of integrated positron emission tomography- computerized tomography scan (PET-CT) guided therapy.(2-5) More recently, brentuximab vedotin in com bination with AVD has been shown to be superior to ABVD.(5) Routine upfront use of BEACOPP is not practicable in many centers and brentuximab is not economically viable at this point.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research